DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Price Performance

DRRX opened at $0.79 on Monday. DURECT has a fifty-two week low of $0.70 and a fifty-two week high of $1.88. The company’s 50 day moving average price is $0.81 and its two-hundred day moving average price is $1.08. The firm has a market capitalization of $24.52 million, a price-to-earnings ratio of -1.30 and a beta of 0.91.

Institutional Trading of DURECT

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its holdings in DURECT by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 14,658 shares during the last quarter. Jane Street Group LLC increased its position in shares of DURECT by 266.0% during the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 28,486 shares during the period. Finally, Richmond Brothers Inc. increased its position in shares of DURECT by 12.2% during the fourth quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock worth $961,000 after buying an additional 138,920 shares during the period. 28.03% of the stock is currently owned by institutional investors.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.